Thyroid disease and the cardiovascular system

Endocrinology and Metabolism Clinics of North America

Volumn 43, Issue 2, 2014, Pages 517-528

  Danzi, Sara ^a   Klein, Irwin ^b,c  

^a QUEENSBOROUGH COMMUNITY COLLEGE   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Private Office   (United States)

Author keywords

Cardiac myocyte; Heart; Hyperthyroidism; Hypothyroidism; Subclinical; Thyroid hormone; Triiodothyronine

Indexed keywords

AMIODARONE; LIOTHYRONINE; THYROID HORMONE; THYRONINE; THYROXINE;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CELL LEVEL; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG WITHDRAWAL; HEART MUSCLE CONTRACTILITY; HEART VENTRICLE TACHYCARDIA; HORMONAL REGULATION; HORMONE ACTION; HORMONE RELEASE; HUMAN; HYPERTHYROIDISM; LIOTHYRONINE BLOOD LEVEL; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SUBCLINICAL HYPOTHYROIDISM; SUPRAVENTRICULAR TACHYCARDIA; TACHYCARDIA; THYROID DISEASE; THYROID HORMONE METABOLISM; THYROTOXICOSIS; TREATMENT PLANNING; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; COMPLICATION; PATHOPHYSIOLOGY; PHYSIOLOGY;

CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; HUMANS; THYROID DISEASES; THYROID HORMONES;

EID: 84901496993     PISSN: 08898529     EISSN: 15584410     Source Type: Journal    
DOI: 10.1016/j.ecl.2014.02.005     Document Type: Review

References (60)

1. Klein I., Danzi S. Thyroid disease and the heart. Circulation 2007, 116:1725-1735.
2. Koenig R.J. Regulation of type 1 iodothyronine deiodinase in health and disease. Thyroid 2005, 15:835-840.
3. Bianco A.C., Kim B.W. Deiodinases: implications of the local control of thyroid hormone action. J Clin Invest 2006, 116:2571-2579.
4. Yu J., Koenig R.J. Induction of type 1 iodothyronine deiodinase to prevent the nonthyroidal illness syndrome in mice. Endocrinology 2006, 147:3580-3585.
5. Davis P.J., Davis F.B. Nongenomic actions of thyroid hormone on the heart. Thyroid 2002, 12:459-466.
6. Dillmann W.H. Cellular action of thyroid hormone on the heart. Thyroid 2002, 12:447-452.
7. Danzi S., Klein I., Portman M.A. Effect of triiodothyronine on gene transcription during cardiopulmonary bypass in infants with ventricular septal defect. Am J Cardiol 2005, 95:787-789.
8. Danzi S., Ojamaa K., Klein I. Triiodothyronine mediated myosin heavy chain gene transcription in the heart. Am J Physiol Heart Circ Physiol 2003, 284:H2255-H2263.
9. Gustavsson M., Verardi R., Mullen D.G., et al. Allosteric regulation of SERCA by phosphorylation-mediated conformational shift of phospholamban. Proc Natl Acad Sci U S A 2013, 110:17338-17343.
10. Ojamaa K., Kenessey A., Klein I. Thyroid hormone regulation of phospholamban phosphorylation in the rat heart. Endocrinology 2000, 141:2139-2144.
11. Danzi S., Klein I. Cardiac specific effects of thyroid hormone analogues. Horm Metab Res 2011, 43:1-6.
12. Ladenson P.W., Kristensen J.D., Ridgway E.C., et al. Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia. N Engl J Med 2010, 362:906-916.
13. Klein I., Ojamaa K. Thyroid hormone and the cardiovascular system. N Engl J Med 2001, 344:501-509.
14. Demers L.M., Spencer C.A. Laboratory medicine practice guidelines: laboratory support for the diagnosis and monitoring of thyroid disease. Thyroid 2003, 13:3-126.
15. Roef G.L., Taes Y.E., Kaufman J.M., et al. Thyroid hormone levels within the reference range are associated with heart rate, cardiac structure, and function in middle-aged men and women. Thyroid 2013, 23:947-954.
16. Selvaraj S., Klein I., Danzi S., et al. Association of Serum Triiodothyronine with B-type natriuretic peptide and severe left ventricular diastolic dysfunction in heart failure with preserved ejection fraction. Am J Cardiol 2012, 110:234-239.
17. Visser W.E., Friesema E.C., Visser T.J. Minireview: thyroid hormone transporters: the knowns and the unknowns. Mol Endocrinol 2011, 25:1-14.
18. Friesema E.C., Jansen J., Jachtenberg J.W., et al. Effective cellular uptake and efflux of thyroid hormone by human monocarboxylate transporter 10. Mol Endocrinol 2008, 22:1357-1369.
19. Danzi S., Klein I. Thyroid hormone and the cardiovascular system. Med Clin North Am 2012, 96:257-268.
20. Pearce E.N., Yang Q., Benjamin E.J., et al. Thyroid function and left ventricular structure and function in the Framingham Heart Study. Thyroid 2010, 20:367-373.
21. Dahl P., Danzi S., Klein I. Thyrotoxic cardiac disease. Curr Heart Fail Rep 2008, 5:170-176.
22. Klein I. Endocrine disorders and cardiovascular disease. Braunwald's heart disease, chapter 86 2011, 1829-1843. WB Saunders and Company, St. Louis (MO). 9th edition. R.O. Bonow, D.L. Mann, D.P. Zipes (Eds.).
23. Marvisi M., Brianti M., Marani G., et al. Hyperthyroidism and pulmonary hypertension. Respir Med 2002, 96:215-220.
24. Ismail H.M. Reversible pulmonary hypertension and isolated right-sided heart failure associated with hyperthyroidism. J Gen Intern Med 2007, 22:148-150.
25. Danzi S., Klein I. Thyroid hormone and blood pressure regulation. Curr Hypertens Rep 2003, 5:513-520.
26. Mintz G., Pizzarello R., Klein I. Enhanced left ventricular diastolic function in hyperthyroidism: noninvasive assessment and response to treatment. J Clin Endocrinol Metab 1991, 73:146-150.
27. Klein I., Danzi S. The cardiovascular system in thyrotoxicosis. Werner & Ingbar's the thyroid: a fundamental and clinical text, chapter 31 2012, 559-568. Lippincott Williams & Wilkins, Philadelphia. 10th edition. L. Braverman, R. Utiger (Eds.).
28. Bahn R.S., Burch H.B., Cooper D.S., et al. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Endocr Pract 2011, 17:456-520.
29. Sawin C.T., Geller A., Wolf P.A., et al. Low serum thyrotropin levels as a risk factor for atrial fibrillation in older persons. N Engl J Med 1994, 33:1249-1252.
30. Klein I., Danzi S. The cardiovascular system in hypothyroidism. Werner & Ingbar's the thyroid: a fundamental and clinical text 2012, 774-780. Lippincott Williams & Wilkins, Philadelphia, Chapter 53. 10th edition. L. Braverman, R. Utiger (Eds.).
31. Parle J.V., Maisonneuve P., Sheppard M.C., et al. Prediction of all-cause and cardiovascular mortality in elderly people from one low serum thyrotropin result: a 10-year cohort study. Lancet 2001, 358:861.
32. Rush J., Danzi S., Klein I. Role of thyroid disease in the development of statin-induced myopathy. Endocrinologist 2006, 16:279.
33. Cappola A.R., Ladenson P.W. Hypothyroidism and atherosclerosis. J Clin Endocrinol Metab 2003, 88:2438.
34. Hak A.E., Pols H.A., Visser T.J., et al. Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: the Rotterdam Study. Ann Intern Med 2000, 132:270.
35. Kim S.D., Kim S.H., Park K.S., et al. Regression of the increased common carotid artery-intima media thickness in subclinical hypothyroidism after thyroid hormone replacement. Endocr J 2009, 56:753.
36. Garber J.R., Cobin R.H., Gharib H., et al. Clinical practice guidelines for hypothyroidism in adults; cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Thyroid 2012, 22:1200-1235.
37. Rodondi N., den Elzen W.P., Bauer D.C., et al. Subclinical hypothyroidism and the risk of coronary heart disease and mortality. JAMA 2010, 304:1365.
38. Biondi B., Cooper D.S. The clinical significance of subclinical thyroid dysfunction. Endocr Rev 2008, 29:76.
39. Gencer B., Collet T.H., Virgini V., et al. Subclinical thyroid dysfunction and the risk of heart failure events: an individual participant data analysis from 6 prospective cohorts. Circulation 2012, 126:1040-1049.
40. Cappola A.R., Fried L.P., Arnold A.M., et al. Thyroid status, cardiovascular risk, and mortality in older adults. JAMA 2006, 295:1033.
41. Biondi B., Klein I. Hypothyroidism as a risk factor for hypothyroidism. Endocrine 2004, 24:1-13.
42. Taddei S., Caraccio N., Virdis A., et al. Impaired endothelium-dependent vasodilatation in subclinical hypothyroidism: beneficial effect of levothyroxine therapy. J Clin Endocrinol Metab 2003, 88:3731.
43. Iervasi G., Molinaro S., Landi P., et al. Association between increased mortality and mild thyroid dysfunction in cardiac patients. Arch Intern Med 2007, 167:1526-1532.
44. Razvi S., Weaver J.U., Butler T.J., et al. Levothyroxine treatment of subclinical hypothyroidism, fatal and nonfatal cardiovascular events, and mortality. Arch Intern Med 2012, 172:811-817.
45. Wartofsky L. Combination L-T3 and L-T4 therapy for hypothyroidism. Curr Opin Endocrinol Diabetes Obes 2013, 20:460-466.
46. Klein I., Danzi S. Thyroid hormone treatment to mend a broken heart. J Clin Endocrinol Metab 2008, 93:1172-1174.
47. Boelen A., Maas M.A., Lowik C.W., et al. Induced illness in interleukin-6 (IL-6) knock-out mice: a causal role of IL-6 in the development of the low 3,5,3'-triiodothyronine syndrome. Endocrinology 1996, 137:5250-5254.
48. Lubrano V., Pingitore A., Carpi A., et al. Relationship between triiodothyronine and proinflammatory cytokines in chronic heart failure. Biomed Pharmacother 2010, 64:165-169.
49. Iervasi G., Pingitore A., Landi P., et al. Low-T3 syndrome: a strong prognostic predictor of death in patients with heart disease. Circulation 2003, 107:708-713.
50. Danzi S., Klein I. Changes in thyroid hormone metabolism and gene expression in the failing heart: therapeutic implications. Thyroid and heart failure, from pathophysiology to clinics 2009, 97-107. Springer-Verlag, Italy, Chapter 10. G. Iervasi, A. Pingitore (Eds.).
51. Danzi S., Klein I. Alterations in thyroid hormones which accompany cardiovascular disease. Clinical Thyroidology 2009, 21:3-5.
52. Zhang B., Peng W., Wang C., et al. A low fT3 level as a prognostic marker in patients with acute myocardial infarctions. Intern Med 2012, 51:3009-3015.
53. Nicolini G., Pitto L., Kusmic C., et al. New insights into mechanisms of cardioprotection mediated by thyroid hormones. J Thyroid Res 2013, 2013:264387.
54. 3 improves left ventricular function in an animal model of myocardial infarction-induced congestive heart failure. Circ Heart Fail 2009, 2:243-252.
55. Pingitore A., Galli E., Barison A., et al. Acute effects of triiodothyronine (T3) replacement therapy in patients with chronic heart failure and low-T3 syndrome: a randomized, placebo-controlled study. J Clin Endocrinol Metab 2008, 93:1351-1358.
56. DeGroot L.J. Non-thyroidal illness syndrome is a manifestation of hypothalamic-pituitary dysfunction, and in view of current evidence, should be treated with appropriate replacement therapies. Crit Care Clin 2006, 22:57-86.
57. Coceani M., Iervasi G., Pingitore A., et al. Thyroid hormone and coronary artery disease: from clinical correlations to prognostic implications. Clin Cardiol 2009, 32:380-385.
58. Cohen-Lehman J., Dahl P., Danzi S., et al. Effects of amiodarone on thyroid function. Nat Rev Endocrinol 2010, 6:34-41.
59. Bogazzi F., Bartalena L., Cosci C., et al. Treatment of type II amiodarone-induced thyrotoxicosis by either iopanoic acid or glucocorticoids: a prospective, randomized study. J Clin Endocrinol Metab 1999, 88:2003.
60. Danzi S., Klein I. Amiodarone-induced thyroid dysfunction. J Intensive Care Med 2013, [Epub ahead of print].